Authors
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Closing Thoughts on Bispecific Antibodies and the Future of R/R MM TreatmentThe panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Alina Markova, MD, on the Future of Topical Ruxolitinib in Cutaneous Chronic GVHD and Multidisciplinary ImplicationsAlina Markova, MD, speaks about future research efforts for topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease, and multidisciplinary implications of current research.
Latest:
Fostering a Team-Based Approach to Elevate Neuro-Oncology CareSpecialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
Latest:
Closing Thoughts, Future Perspectives, and Key Takeaways in the Treatment of Epithelioid SarcomaPanelists discuss how early recognition, accurate diagnosis through histopathology and molecular testing, and multidisciplinary collaboration are critical for optimizing treatment strategies in epithelioid sarcoma (ES), while future research into targeted therapies holds promise for improving outcomes, especially in advanced cases.
Latest:
Tiffany Sia, MD, on Procedural Interventions for Gynecologic Malignancies With Oligoprogressive Disease During ICITiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.
Latest:
The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant ChemotherapyExperts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Latest:
Addressing Rising Cancer Incidence and Burden in Younger PopulationsPrimary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.
Latest:
Lilian Gien, MD, Talks Next Steps for Immunotherapy Research in Recurrent Clear Cell Carcinoma of the OvaryLillian Gien, MD, spoke about continued use of immunotherapy in patients with recurrent clear cell carcinoma of the ovary following results of a trial examining pembrolizumab plus epacadostat.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A MutationJohnathan Q. Trinh, MD, et al discuss a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor.
